


Catalog # 10-3977

C19-9

CAS# 1477482-47-5

N-[(E)-(3-Hydroxy-4-methoxyphenyl)methylideneamino]-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (E)-N'-(3-Hydroxy-4-methoxybenzylidene)-4,5,6,7-tetrahydro-1H-indazole-3-carbohydrazide

Lot # FBA9012



C19-9 is a novel non-RGD inhibitor of the integrin $\alpha\beta_3$ receptor ($K_D = 102$ nM). It was active against the human prostate carcinoma epithelial cell line 22RV1 ($IC_{50} = 467$ nM) and human prostate cancer organoids ($IC_{50} = 652$ nM). C19-9 was active *in vivo* in 22RV1 mouse xenografts and blocked growth in enzalutamide-resistant mouse CRPC xenografts.

References:

- 1) Pang *et al.* (2023), *Discovery of C19-9 as a novel non-RGD inhibitor of $\alpha\beta_3$ to overcome enzalutamide resistance in castration-resistant prostate cancer*; Signal Transduct. Target Ther. **8** 60

PHYSICAL DATA

Molecular Weight: 314.35
Molecular Formula: C₁₆H₁₈N₄O₃
Purity: >98% by TLC
NMR: (Conforms)
Solubility: DMSO (at least 50 mg/ml)
Physical Description: White to off-white solid
Storage and Stability: Store as supplied at -20°C for up to 2 years from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.